thought leadership

ProPharma’s team of dedicated experts is at the forefront of both existing and emerging industry trends. ProPharma’s team inspires tomorrow by leveraging rich data insights across our service lines and functional areas to develop innovative solutions that answer the most complex needs of both existing and prospective clients.

Flywheel swoosh

Why Medical Information Is Critical to Adverse Event Reporting

Adverse event (AE) reporting is one of the most critical responsibilities across the pharmaceutical industry. At its core, pharmacovigilance (PV) exists to protect patient safety and maintain regulatory compliance. Yet the success of any PV program depends heavily on accurate, timely AE...

colleagues working at the computer in a contact center

Medical Information

Rethinking the Role of the Medical Information Contact Center: An Untapped Resource for Medical Writing

In many organizations, teams are being asked to deliver greater value with limited resources. This has prompted a closer look at existing functions to identify where capabilities may be...

Person holding tablet in a lab while where a lab coat

Quality & Compliance

Rethinking Biometrics Resourcing in Modern Clinical Trials

Rethinking biometrics as a strategic function to improve consistency, scalability, and clinical trial performance. Biometrics has become one of the most critical components of clinical development....

Medical Information

The Hidden Value of Medical Information: Strengthening Brand Trust

Pharmaceutical companies are not always portrayed positively in the media or fully appreciated by customers. A common perception persists that the industry prioritizes revenue over patient...

Man reading a document

Quality & Compliance

Understanding For-Cause Audits: A GMP Case Study

Opening Scene: A Routine Batch Review, Or So It Seemed It started, as many GMP investigations do, with a routine batch review. But this time, the review wasn't happening on the manufacturing floor;...

Regulatory Sciences

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

Why Sponsors Should Pressure-Test Their IND Before Submission For many sponsors, the Investigational New Drug (IND) application is viewed as a procedural milestone, the point at which a development...

Medical Professional Working On Secure iPad cybersecurity

Regulatory Sciences

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

Cybersecurity threats are no longer theoretical risks for medical device manufacturers. They are operational, regulatory, and patient safety events unfolding in real time. Recent cybersecurity...

Coworkers collaborating on laptop

Medical Information

The Strategic Importance of a Consumer Health Service Line

In today's rapidly evolving healthcare landscape, Consumer Health brands face growing expectations to provide timely, accurate, and accessible support directly to their consumers. From nutritional...

Person typing on laptop with overlays for AI and ethics

Quality & Compliance

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

The FDA's April 2026 Warning Letter to Purolea Cosmetics Lab is a notable milestone for the pharmaceutical industry. While there have been prior Warning Letters involving products that incorporate...

woman-in-lab-coat-wearing-headset-stethoscope-typing-on-laptop

Medical Information

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Global Market Reach

As the healthcare and pharmaceutical industries continue to grow globally, many companies are increasingly leaning into offshoring medical information services. Medical information teams play a...

Professional workers collaborating in an office

FSP Solutions

Preparing for EMA Policy 0070: How to Stay Ahead of the Anonymization Curve

Under Policy 0070 from the European Medicines Agency (EMA), sponsors are required to submit anonymized clinical reports for publication on the Clinical Data Publication (CDP) portal. Once published,...

Row of customer service professionals wearing headset one person smiling at camera

Medical Information

Navigating Medical Inquiries Across Europe: Why Multilingual Support Matters for MAHs

Europe is one region — but it is far from uniform. For Marketing Authorization Holders (MAHs), providing consistent, compliant Medical Information (MI) support across the continent requires...

Business professionals meeting at table

Quality & Compliance

From Reactive to Proactive: The New MAH Compliance Standard

As global regulatory expectations evolve, one trend is unmistakably clear: Marketing Authorization Holders (MAHs) must take a more proactive role in monitoring and managing supplier compliance....

Regulatory Sciences

The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

For decades, FDA's Investigational New Drug (IND) application has been viewed primarily as a regulatory gateway. Submit the application, obtain FDA's approval to proceed, and begin clinical trials....

note-taking-on-clipboard

Medical Information

Mastering the Pharmacovigilance System Master File (PSMF): A Guide to Inspection Readiness

In the highly regulated pharmaceutical industry, maintaining a robust pharmacovigilance system is essential to ensure patient safety and regulatory compliance. One of the most critical documents...

health-care-worker-wearing-headset-working-on-laptop

Medical Information

A Smarter Front‑Desk Model: Multilingual Contact Center Support for MAHs

For Marketing Authorization Holders (MAHs), ensuring that healthcare professionals (HCPs) and patients can easily access the organization is essential to delivering safe, compliant, and high‑quality...

What to Expect During the NDA Review Process

Compiling and submitting a New Drug Application (NDA) submission is a complicated and intensive activity. Once you have submitted your application to FDA, you may be curious about what can you expect...

Several business professionals talking around glass conference table

Safety Data Exchange Agreements (SDEAs) and Pharmacovigilance Agreements (PVAs) – An Overview

A Safety Data Exchange Agreement (SDEA) or Pharmacovigilance Agreement (PVA) is a legal written contract which ensures that all safety data, PV tasks and responsibilities are detailed between two or...

child-receiving-medical-care-rare-disease

The End of the FDA's Rare Pediatric Disease Priority Review Voucher Program

What’s Next for Rare Disease Innovation? For children suffering from rare and often life-threatening diseases, access to new and effective treatments can mean the difference between life and death....

An Overview of the PSMF: Pharmacovigilance System Master File

What is a PSMF? The EU Pharmacovigilance System Master File (PSMF) is a legally required document created and maintained by a Marketing Authorisation Holder (MAH). Essentially, the document is a...

Hands working on a laptop.

FDA's Expedited Programs Explained

In order to incentivize the development of therapies (drugs biologics) to fill unmet medical needs for treatment of serious conditions, the FDA has developed various programs to expedite drug...

Illustration of the Common Technical Document (CTD) Triangle

The Importance of the eCTD Structure for FDA Approval

The Importance of the eCTD To harmonize the process of regulatory reviews for global drug development, a unified structure was developed and implemented for electronic Common Technical Document...